The financing round also included participation from GSR Ventures and other strategic partners.
The investment will enable Deep 6 AI to meet the demand from healthcare providers, pharma companies, and contract research organisations for the company’s suite of AI-driven tools.
These tools are designed to optimise clinical trials design and accelerate the recruitment of clinical trials.
Point72 Ventures partner Daniel Gwak said: “Deep 6’s track record in accelerating clinical trials through improved patient recruitment and trial design has resonated strongly with major healthcare providers and trial sponsors, who recognise Deep 6 as the clear leader in this field.”
As part of the investment, Gwak will join the board of Deep 6 AI as one of the directors.
Deep 6 uses AI to recall clinical trial qualification criteria and match against structured and unstructured repositories of patient health data at participating trial sites.
It allows trial sponsors and healthcare providers to find qualified patients before they even invest in recruiting patients and activating trial sites.
Deep 6 AI CEO Wout Brusselaers said: “Point72 Ventures’ emphasis on backing best-in-class category leaders validates Deep 6’s reputation as the product and technology leader in this new industry.
“Their investment will allow us to rapidly scale up to meet the high demand for our software, as health systems recognise the significant opportunity from leveraging AI to turn their research efforts into a growth and profit centre.”
The proceeds from the financing will be used to accelerate the growth of the company’s healthcare providers and trial sponsors’ network.
Part of the funds will also be used to expand Deep 6 AI’s portfolio of AI-native software products.